From: Risk factors and outcome of COVID-19 in patients with hematological malignancies
Variables | Log. Regr. COVID-19 Stage II Ba (n = 367) | Log. Regr. COVID-19 Mortality (n = 367) | ||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | R (95% CI) | p value | |
Patient age > 70 years old | 2.25 (1.45–3.5) | < 0.0001 | ns |  | 3.1 (1.9–5) | < 0.0001 | 2.1 (1.2–3.8) | 0.011 |
Patient age | Â | Â | ns | Â | Â | Â | ns | Â |
 0–20 | 1 |  |  |  | 1 |  |  |  |
 21–70 | 5.6 (1.2–25) | 0.02 |  |  | 0.7 (0.22–2.3) | 0.59 |  |  |
 >70 | 11.5 (2.5–52) | 0.002 |  |  | 2.3 (0.7–7.5) | 0.16 |  |  |
Sex male | 1.41 (0.93–2.1) | 0.09 | ns |  | 0.95 (0.6–1.5) | 0.8 |  |  |
Baseline disease | Â | Â | ns | Â | Â | Â | ns | Â |
 AML | 1 |  |  |  | 1 |  |  |  |
 ALL | 0.8 (0.3–2) | 0.68 |  |  | 0.6 (0.22–1.67) | 0.3 |  |  |
 MDS | 1.3 (0.5–3.4) | 0.5 |  |  | 0.69 (0.25–1.9) | 0.47 |  |  |
 CMPD | 2.7 (1.1–6.8) | 0.032 |  |  | 0.6 (0.23–1.5) | 0.3 |  |  |
 NHL | 1.37 (0.7–2.6) | 0.3 |  |  | 0.63 (0.3–1.2) | 0.3 |  |  |
 CLL | 2.9 (1.12–7.6) | 0.03 |  |  | 0.7 (0.35–1.06) | 0.06 |  |  |
 Plasmatic cell disorder | 0.98 (0.5–1.8) | 0.9 |  |  | 0.7 (0.35–1.4) | 0.3 |  |  |
 AA or auto-immune disorders | 0.3 (0.09–1.1) | 0.07 |  |  | 0.08 (0.01–0.69) | 0.02 |  |  |
Disease status | Â | Â | ns | Â | Â | Â | Â | Â |
 CR/PR/not requiring therapy | 1 |  |  |  | 1 |  |  |  |
 Rel/Ref/Prog | 1.49 (0.96–2.3) | 0.076 |  |  | 3.78 (2.3–6) | < 0.0001 | 2.9 (1.6–5.2) | < 0.0001 |
Procedure | Â | Â | ns | Â | Â | Â | ns | Â |
 Allo-SCT | 1 |  |  |  | 1 |  |  |  |
 ASCT | 0.75 (0.37–1.5) | 0.4 |  |  | 1.04 (0.43–2.5) | 0.9 |  |  |
 Non-SCT | 1.57 (0.92–2.6) | 0.09 |  |  | 1.95 (1.03–3.7) | 0.048 | ns |  |
Chemotherapy 40 days before COVID-19 | 1.18 (0.7–1.8) | 0.4 | ns |  | 1.76 (1.1–2.79) | 0.016 | ns |  |
Disease Dx within 40 days of COVID-19 | 1.1 (0.6–1.9) | 0.7 | ns |  | 2.2 (1.24–3.9) | 0.007 | ns |  |
ECOG 3–4 | 1.8 (1.14–2.98) | 0.012 | ns |  | 3.7 (2.2–6.1) | < 0.0001 | 2.56 (1.4–4.7) | 0.003 |
Active smoking | 1.88 (0.89–3.9) | 0.094 | ns |  | 1.3 (0.6–2.79) | 0.4 |  |  |
Arterial hypertension | 2.26 (1.4–3.49) | < 0.0001 | 2 (1.3–3.2) | 0.002 | 2.6 (1.6–4.16) | < 0.0001 | ns |  |
Cardiomyopathy | 1.98 (1.1–3.4) | 0.015 | ns |  | 1.6 (0.9–2.88) | 0.089 | ns |  |
Dyslipidemia | 1.6 (1–2.59) | 0.049 | ns |  | 1.86 (1.1–3) | 0.015 | ns |  |
Place of SARS-CoV-2 infection | Â | Â | ns | Â | Â | Â | Â | Â |
 Outpatient | 1 |  |  |  | 1 |  |  |  |
 Inpatient in specialized hospital | 1.1 (0.6–1.8) | 0.69 |  |  | 1.05 (0.3–3.6) | 0.9 |  |  |
ALC < 0.5 × 109/L | 1.7 (1.1–2.68) | 0.014 | 1.7 (1.1–2.7) | 0.015 | 2.25 (1.6–3.6) | 0.001 | ns |  |
ANC < 0.5 × 109/L | 1.4 (0.7–2.7) | 0.27 | ns |  | 3.4 (1.8–6.67) | < 0.0001 | 2.8 (1.3–6.1) | 0.01 |
Platelet count (× 109/L) |  |  |  |  |  |  | ns |  |
 < 20 × 109/L | 1.7 (0.8–3.66) | 0.16 |  |  | 4.44 (2.1–9.4) | < 0.0001 |  |  |
 21–50 × 109/L | 1.18 (0.6–2.26) | 0.6 |  |  | 3.6 (1.8–7.05) | < 0.0001 |  |  |
 > 50 × 109/L | 1 |  |  |  | 1 |  |  |  |
CRP > 20 mg/dL | 3.1 (1.9–4.9) | < 0.0001 | 2.67 (1.6–4.3) | < 0.0001 | 4 (2.2–7.18) | < 0.0001 | 3.3 (1.7–6.4) | < 0.0001 |
IL-6 > 50 pg/mLb | 3.2 (1.38–7.35) | 0.007 | NT |  | 2.7 (1.1–6.59) | 0.028 | NT |  |
Ferritin levelsb | Â | Â | NT | Â | Â | Â | NT | Â |
 <500 µg/mL | 1 |  |  |  | 1 |  |  |  |
 501–1000 µg/mL | 1.18 (0.4–3.2) |  |  |  | 1 (0.24–4.1) | 0.99 |  |  |
 >1001 µg/mL | 2.4 (1.1–5.35) | 0.03 |  |  | 2.8 (1–7.9) | 0.05 |  |  |
D dimer > 500 ng/mLb | 1.6 (1.02–2.6) | 0.04 | NT |  | 1.34 (0.8–2.3) | 0.2 | NT |  |